Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma<img src="http://feeds.foxbusiness.com/~r/foxbusiness/latest/~4/302062052" height="1" width="1"/><img src="http://feeds.foxnews.com/~r/foxnews/business/~4/302063607" height="1" width="1"/>
http://feeds.foxnews.com/~r/foxnews/business/~3/302063607/